JP2020509756A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020509756A5 JP2020509756A5 JP2019549389A JP2019549389A JP2020509756A5 JP 2020509756 A5 JP2020509756 A5 JP 2020509756A5 JP 2019549389 A JP2019549389 A JP 2019549389A JP 2019549389 A JP2019549389 A JP 2019549389A JP 2020509756 A5 JP2020509756 A5 JP 2020509756A5
- Authority
- JP
- Japan
- Prior art keywords
- e100ff
- antibody
- antibody according
- isolated
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical class 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 8
- 230000035772 mutation Effects 0.000 claims 8
- 235000001014 amino acid Nutrition 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims 5
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 3
- 230000002378 acidificating effect Effects 0.000 claims 3
- 239000012636 effector Substances 0.000 claims 3
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 3
- 230000007935 neutral effect Effects 0.000 claims 3
- 230000004962 physiological condition Effects 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 claims 2
- 229920002971 Heparan sulfate Polymers 0.000 claims 2
- 108090000054 Syndecan-2 Proteins 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 239000000611 antibody drug conjugate Substances 0.000 claims 2
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 210000000440 neutrophil Anatomy 0.000 claims 2
- 210000005259 peripheral blood Anatomy 0.000 claims 2
- 239000011886 peripheral blood Substances 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- 102100032530 Glypican-3 Human genes 0.000 claims 1
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- 241000282567 Macaca fascicularis Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000004236 Ponceau SX Substances 0.000 claims 1
- 208000003874 Simpson-Golabi-Behmel syndrome Diseases 0.000 claims 1
- 230000006044 T cell activation Effects 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000017455 cell-cell adhesion Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 239000013638 trimer Substances 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023002879A JP7573659B2 (ja) | 2017-03-14 | 2023-01-12 | 酸性ｐＨでＶＩＳＴＡに結合する抗体 |
| JP2024179648A JP2025023919A (ja) | 2017-03-14 | 2024-10-15 | 酸性ｐＨでＶＩＳＴＡに結合する抗体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762471196P | 2017-03-14 | 2017-03-14 | |
| US62/471,196 | 2017-03-14 | ||
| US201862636746P | 2018-02-28 | 2018-02-28 | |
| US62/636,746 | 2018-02-28 | ||
| PCT/US2018/022230 WO2018169993A1 (en) | 2017-03-14 | 2018-03-13 | Antibodies binding to vista at acidic ph |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023002879A Division JP7573659B2 (ja) | 2017-03-14 | 2023-01-12 | 酸性ｐＨでＶＩＳＴＡに結合する抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020509756A JP2020509756A (ja) | 2020-04-02 |
| JP2020509756A5 true JP2020509756A5 (https=) | 2021-04-30 |
| JP7211961B2 JP7211961B2 (ja) | 2023-01-24 |
Family
ID=63522565
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019549389A Active JP7211961B2 (ja) | 2017-03-14 | 2018-03-13 | 酸性ｐＨでＶＩＳＴＡに結合する抗体 |
| JP2023002879A Active JP7573659B2 (ja) | 2017-03-14 | 2023-01-12 | 酸性ｐＨでＶＩＳＴＡに結合する抗体 |
| JP2024179648A Pending JP2025023919A (ja) | 2017-03-14 | 2024-10-15 | 酸性ｐＨでＶＩＳＴＡに結合する抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023002879A Active JP7573659B2 (ja) | 2017-03-14 | 2023-01-12 | 酸性ｐＨでＶＩＳＴＡに結合する抗体 |
| JP2024179648A Pending JP2025023919A (ja) | 2017-03-14 | 2024-10-15 | 酸性ｐＨでＶＩＳＴＡに結合する抗体 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US11603406B2 (https=) |
| EP (1) | EP3595720A4 (https=) |
| JP (3) | JP7211961B2 (https=) |
| KR (2) | KR20240151866A (https=) |
| CN (2) | CN118894937A (https=) |
| AU (2) | AU2018236218B2 (https=) |
| BR (1) | BR112019019108A2 (https=) |
| CA (1) | CA3054067A1 (https=) |
| CL (2) | CL2019002610A1 (https=) |
| CO (1) | CO2019010943A2 (https=) |
| IL (2) | IL269240B1 (https=) |
| MX (1) | MX2024003316A (https=) |
| MY (1) | MY200609A (https=) |
| PE (2) | PE20250933A1 (https=) |
| SG (1) | SG11201907848YA (https=) |
| TW (2) | TWI890190B (https=) |
| WO (1) | WO2018169993A1 (https=) |
| ZA (1) | ZA201905525B (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104761637B (zh) | 2006-03-31 | 2021-10-15 | 中外制药株式会社 | 调控抗体血液动力学的方法 |
| ES2595638T3 (es) | 2007-09-26 | 2017-01-02 | Chugai Seiyaku Kabushiki Kaisha | Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR |
| KR102057826B1 (ko) | 2008-04-11 | 2019-12-20 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| EP2647706B1 (en) | 2010-11-30 | 2023-05-17 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
| MX352889B (es) | 2011-02-25 | 2017-12-13 | Chugai Pharmaceutical Co Ltd | Anticuerpo de fc especifico para fcyriib. |
| JP6322411B2 (ja) | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| KR20230143201A (ko) | 2011-11-30 | 2023-10-11 | 추가이 세이야쿠 가부시키가이샤 | 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약 |
| SG11201404751UA (en) | 2012-02-09 | 2014-09-26 | Chugai Pharmaceutical Co Ltd | Modified fc region of antibody |
| SG10201709559PA (en) | 2012-08-24 | 2017-12-28 | Chugai Pharmaceutical Co Ltd | Fcγriib-specific fc region variant |
| WO2014159562A1 (en) * | 2013-03-14 | 2014-10-02 | Bristol-Myers Squibb Company | Combination of dr5 agonist and anti-pd-1 antagonist and methods of use |
| CN105246914B (zh) | 2013-04-02 | 2021-08-27 | 中外制药株式会社 | Fc区变体 |
| BR112017011235A2 (pt) | 2014-12-19 | 2018-02-06 | Chugai Pharmaceutical Co Ltd | anticorpos anti-c5 e métodos de uso |
| KR101860280B1 (ko) | 2014-12-19 | 2018-05-21 | 추가이 세이야쿠 가부시키가이샤 | 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법 |
| KR102605798B1 (ko) | 2015-02-05 | 2023-11-23 | 추가이 세이야쿠 가부시키가이샤 | 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용 |
| WO2017110981A1 (en) | 2015-12-25 | 2017-06-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| EP3494991A4 (en) | 2016-08-05 | 2020-07-29 | Chugai Seiyaku Kabushiki Kaisha | COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES |
| KR20250159733A (ko) | 2017-01-11 | 2025-11-11 | 브리스톨-마이어스 스큅 컴퍼니 | Psgl-1 길항제 및 그의 용도 |
| WO2018139623A1 (en) | 2017-01-30 | 2018-08-02 | Chugai Seiyaku Kabushiki Kaisha | Anti-sclerostin antibodies and methods of use |
| PE20250933A1 (es) | 2017-03-14 | 2025-04-02 | Five Prime Therapeutics Inc | Anticuerpos de union a vista a ph acido |
| US11220550B2 (en) | 2017-05-25 | 2022-01-11 | Bristol-Myers Squibb Company | Antagonistic anti-CD40 antibodies and methods of antagonizing CD40 activity |
| BR112020019083A2 (pt) | 2018-03-21 | 2020-12-29 | Five Prime Therapeutics, Inc. | Anticorpos, ácido nucleico, composições, célula e métodos para preparar um anticorpo, para tratar câncer, para tratar uma doença infecciosa, para tratar uma inflamação, para a identificação de um anticorpo, para melhorar a eficácia antitumoral de um anticorpo, para melhorar a farmacocinética de um anticorpo, para selecionar um anticorpo, para melhorar a eficácia de anticorpos, para isolar anticorpos, para detectar vista em uma amostra e para tratar câncer |
| GB201814562D0 (en) | 2018-09-07 | 2018-10-24 | Hummingbird Bioscience Pte Ltd | Vista antigen-binding molecules |
| US20190300610A1 (en) * | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Pte. Ltd. | Vista antigen-binding molecules |
| PE20210687A1 (es) * | 2018-07-11 | 2021-04-08 | Bristol Myers Squibb Co | Anticuerpos de union a vista a ph acido |
| CN112740043A (zh) * | 2018-07-20 | 2021-04-30 | 皮埃尔法布雷医药公司 | Vista受体 |
| AR117091A1 (es) | 2018-11-19 | 2021-07-07 | Bristol Myers Squibb Co | Anticuerpos monoclonales antagonistas contra cd40 y sus usos |
| CA3149719A1 (en) * | 2019-09-19 | 2021-03-25 | Bristol-Myers Squibb Company | Antibodies binding to vista at acidic ph |
| AU2020403913B2 (en) | 2019-12-18 | 2024-10-10 | F. Hoffmann-La Roche Ag | Bispecific anti-CCL2 antibodies |
| US20240132593A1 (en) * | 2021-02-18 | 2024-04-25 | Kineta, Inc. | Anti-vista antibodies and uses thereof |
| EP4373848A2 (en) | 2021-07-22 | 2024-05-29 | University of Dundee | Therapeutic muteins |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4997913A (en) | 1986-06-30 | 1991-03-05 | Oncogen | pH-sensitive immunoconjugates and methods for their use in tumor therapy |
| US5605821A (en) | 1989-03-08 | 1997-02-25 | Board Of Regents Of The University Of Oklahoma | Expression control sequences of the P-selectin gene |
| ES2183851T3 (es) | 1990-07-17 | 2003-04-01 | Univ Oklahoma | Ligando de gmp-140. |
| WO1994010309A1 (en) | 1992-10-23 | 1994-05-11 | Genetics Institute, Inc. | Novel p-selectin ligand protein |
| US5843707A (en) | 1992-10-23 | 1998-12-01 | Genetics Institute, Inc. | Nucleic acid encoding a novel P-selectin ligand protein |
| US6277975B1 (en) | 1992-10-23 | 2001-08-21 | Genetics Institute, Inc. | Fusions of P-selectin ligand protein and polynucleotides encoding same |
| AU681369B2 (en) | 1992-11-16 | 1997-08-28 | Board Of Regents Of The University Of Oklahoma, The | Glycoprotein ligand for P-selectin and methods of use thereof |
| WO1995030001A2 (en) | 1994-04-28 | 1995-11-09 | Genetics Institute, Inc. | Novel p-selectin ligand protein |
| KR100523506B1 (en) | 1995-08-03 | 2005-10-24 | Peptide and O-glycan inhibitors of selectin mediated inflammation | |
| US5998588A (en) | 1995-09-01 | 1999-12-07 | University Of Washington | Interactive molecular conjugates |
| WO2000078961A1 (en) | 1999-06-23 | 2000-12-28 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| JP2002508167A (ja) | 1997-12-18 | 2002-03-19 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | １１０個のヒト分泌タンパク質 |
| WO2000000610A2 (en) | 1998-06-26 | 2000-01-06 | Incyte Pharmaceuticals, Inc. | Human signal peptide-containing proteins |
| NZ531664A (en) | 1998-09-01 | 2005-07-29 | Genentech Inc | Pro1317 polypeptides and sequences thereof with homology to the semaphorin B glycoprotein family |
| AU5249700A (en) | 1999-07-08 | 2001-01-30 | Protegene Inc. | Human proteins having hydrophobic domains and dnas encoding these proteins |
| WO2001073028A2 (en) | 2000-03-24 | 2001-10-04 | Genetics Institute, Llc | A p-selectin glycoprotein ligand (psgl-1) binding protein and uses therefor |
| US7744888B2 (en) | 2001-08-03 | 2010-06-29 | Abgenomics Cooperatief U.A. | Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies |
| US20040116333A1 (en) | 2001-08-03 | 2004-06-17 | Rong-Hwa Lin | Modulators of P-selectin glycoprotein ligand 1 |
| US20060141456A1 (en) | 2002-06-12 | 2006-06-29 | Cynthia Edwards | Methods and compositions for milieu-dependent binding of a targeted agent to a target |
| AU2003258714A1 (en) | 2002-09-06 | 2004-03-29 | Cytos Biotechnology Ag | Immune modulatory compounds and methods |
| US20050260711A1 (en) * | 2004-03-30 | 2005-11-24 | Deepshikha Datta | Modulating pH-sensitive binding using non-natural amino acids |
| UY28886A1 (es) | 2004-05-10 | 2005-12-30 | Boehringer Ingelheim Int | Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18 |
| ES2655833T3 (es) | 2004-05-11 | 2018-02-21 | AbGenomics Coöperatief U.A. | Epítopos que inducen la muerte de células T |
| PT1781682E (pt) | 2004-06-24 | 2013-05-14 | Mayo Foundation | B7-h5, um polipéptido coestimulante |
| US8231872B2 (en) | 2005-04-25 | 2012-07-31 | The Trustees Of Dartmouth College | Regulatory T cell mediator proteins and uses thereof |
| US8236304B2 (en) | 2005-04-25 | 2012-08-07 | Trustees Of Dartmouth College | Use of PD-L3 proteins and PD-L3 specific antibodies or antibody fragments to regulate CD4+ and CD8+ T cell immunity |
| WO2007033959A2 (en) | 2005-09-19 | 2007-03-29 | Vib Vzw | Use of p-selectin glycoprotein ligand 1 in modulation of hematogenous metastasis of lymphomas |
| US20070160601A1 (en) | 2005-12-09 | 2007-07-12 | Angela Widom | Neutralizing antibodies against primate psgl-1 and uses therefor |
| US7655778B2 (en) | 2006-02-28 | 2010-02-02 | Curonix Co., Ltd. | SISP-1, a novel p53 target gene and use thereof |
| ATE536369T1 (de) | 2006-10-11 | 2011-12-15 | Ablynx Nv | Im wesentlichen ph-wert-unabhängigerweise an serumproteine bindende aminosäuresequenzen, verbindungen, die diese enthalten, und deren verwendung |
| JP2010534469A (ja) | 2007-07-25 | 2010-11-11 | アストラゼネカ アクチボラグ | Ｋｄｒ指向性標的化結合物質およびその使用 |
| EP2650017A3 (en) | 2008-02-05 | 2014-01-22 | Bristol-Myers Squibb Company | Alpha 5 - beta 1 antibodies and their uses |
| WO2009111507A1 (en) | 2008-03-03 | 2009-09-11 | Dyax Corp. | Metalloproteinase 12 binding proteins |
| US7833530B2 (en) | 2008-05-15 | 2010-11-16 | Selexys Pharmaceuticals Corporation | Methods of inhibiting the PSGL-1-mediated adhesion and chemokine-mediated migration with PSGL-1-specific antibodies |
| JP2012515556A (ja) | 2009-01-23 | 2012-07-12 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 低下したエフェクタ機能を有する安定化Ｆｃポリペプチドおよび使用方法 |
| CN102369296A (zh) | 2009-03-09 | 2012-03-07 | 生物蛋白有限公司 | Mirac蛋白 |
| US10053513B2 (en) | 2009-11-30 | 2018-08-21 | Janssen Biotech, Inc. | Antibody Fc mutants with ablated effector functions |
| MX374075B (es) | 2010-03-26 | 2025-03-05 | Dartmouth College | Proteina mediadora de celula t regulatoria vista, agentes de enlace de vista y uso de los mismos. |
| RU2585489C2 (ru) | 2010-04-27 | 2016-05-27 | Рош Гликарт Аг | КОМБИНИРОВАННАЯ ТЕРАПИЯ АФУКОЗИЛИРОВАННЫМ АНТИТЕЛОМ CD20 И ИНГИБИТОРОМ mTOR |
| MX349622B (es) * | 2010-09-08 | 2017-08-07 | Halozyme Inc | Metodos para evaluar e identificar o evolucionar proteinas terapeuticas condicionalmente activas. |
| EP2718325A4 (en) | 2011-06-13 | 2015-03-11 | ABGENOMICS COöPERATIEF U A | ANTI-PSGL-1 ANTIBODIES AND USES THEREOF |
| US9587014B2 (en) * | 2011-10-28 | 2017-03-07 | Biogen International Neuroscience Gmbh | TDP-43 specific binding molecules |
| JP6181066B2 (ja) | 2011-11-28 | 2017-08-16 | ショー，グレイ，ディー． | 新規な増強型セレクチンアンタゴニスト |
| AU2013229786B2 (en) * | 2012-03-08 | 2017-06-22 | Halozyme, Inc. | Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof |
| JP6285923B2 (ja) | 2012-06-22 | 2018-02-28 | トラスティーズ・オブ・ダートマス・カレッジ | 新規ＶＩＳＴＡ−Ｉｇコンストラクト及び自己免疫、アレルギー性及び炎症性障害の処置のためのＶＩＳＴＡ−Ｉｇの使用 |
| US9890215B2 (en) * | 2012-06-22 | 2018-02-13 | King's College London | Vista modulators for diagnosis and treatment of cancer |
| US9381244B2 (en) | 2012-09-07 | 2016-07-05 | King's College London | VISTA modulators for diagnosis and treatment of cancer |
| EP3508215A3 (en) | 2012-12-03 | 2019-10-02 | Bristol-Myers Squibb Company | Enhancing anti-cancer activity of immunomodulatory fc fusion proteins |
| BR112015029395A2 (pt) * | 2013-05-24 | 2017-09-19 | Medimmune Llc | Anticorpos anti-b7-h5 e seus usos |
| SG11201509982UA (https=) | 2013-06-06 | 2016-04-28 | Igenica Biotherapeutics Inc | |
| WO2015037000A1 (en) | 2013-09-11 | 2015-03-19 | Compugen Ltd | Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases |
| IL292510A (en) | 2013-11-05 | 2022-06-01 | Cognate Bioservices Inc | Combinations of checkpoint inhibitors and therapeutics to treat cancer |
| WO2015097536A2 (en) * | 2013-12-24 | 2015-07-02 | Janssen Pharmaceutical Nv | Anti-vista antibodies and fragments |
| EP3094346B1 (en) | 2014-01-14 | 2019-12-11 | The Trustees Of Dartmouth College | Vista antagonist and methods of use |
| RU2550262C1 (ru) | 2014-02-28 | 2015-05-10 | Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства | Моноклональное антитело против интерлейкина-6 человека и гибридома, продуцирующая данное моноклональное антитело |
| WO2015187359A1 (en) | 2014-06-04 | 2015-12-10 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for targeting a pathway |
| US11123426B2 (en) | 2014-06-11 | 2021-09-21 | The Trustees Of Dartmouth College | Use of vista agonists and antagonists to suppress or enhance humoral immunity |
| PT3166636T (pt) | 2014-07-08 | 2021-06-29 | Sanford Burnham Med Res Inst | Moduladores de psgl-1 e utilizações dos mesmos |
| JOP20150008B1 (ar) * | 2014-11-26 | 2021-08-17 | Janssen Pharmaceutica Nv | أجسام مضادة ل vista وأجزاء منها |
| CA2969730A1 (en) | 2014-12-05 | 2016-06-09 | Immunext, Inc. | Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators |
| JP6800853B2 (ja) | 2014-12-11 | 2020-12-16 | ピエール、ファーブル、メディカマン | 抗ｃ１０ｏｒｆ５４抗体およびその使用 |
| JP6180663B2 (ja) | 2014-12-23 | 2017-08-16 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｔｉｇｉｔに対する抗体 |
| DK3303396T5 (da) * | 2015-05-29 | 2024-10-07 | Bristol Myers Squibb Co | Antistoffer mod ox40 og anvendelser deraf |
| CA2990360C (en) | 2015-06-24 | 2024-02-13 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments |
| WO2017078839A1 (en) | 2015-11-02 | 2017-05-11 | Bioatla, Llc | Conditionally active polypeptides |
| IL260289B (en) | 2016-01-08 | 2022-08-01 | Bioalliance Cv | Tetravalent anti-psgl-1 antibodies and uses thereof |
| WO2017137830A1 (en) * | 2016-02-12 | 2017-08-17 | Janssen Pharmaceutica Nv | Anti-vista (b7h5) antibodies |
| WO2017175058A1 (en) | 2016-04-07 | 2017-10-12 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
| WO2017181109A1 (en) | 2016-04-15 | 2017-10-19 | Michael Molloy | Anti-human vista antibodies and use thereof |
| KR20230119259A (ko) * | 2016-04-15 | 2023-08-16 | 이뮤넥스트, 인크. | 항-인간 vista 항체 및 이의 용도 |
| WO2018027042A1 (en) | 2016-08-03 | 2018-02-08 | Bio-Techne Corporation | Identification of vsig3/vista as a novel immune checkpoint and use thereof for immunotherapy |
| WO2018047143A1 (en) | 2016-09-12 | 2018-03-15 | Aurigene Discovery Technologies Limited | Vista signaling pathway inhibitory compounds useful as immunomodulators |
| KR20250159733A (ko) | 2017-01-11 | 2025-11-11 | 브리스톨-마이어스 스큅 컴퍼니 | Psgl-1 길항제 및 그의 용도 |
| PE20250933A1 (es) | 2017-03-14 | 2025-04-02 | Five Prime Therapeutics Inc | Anticuerpos de union a vista a ph acido |
| WO2018195772A1 (en) | 2017-04-25 | 2018-11-01 | Sun Yat-Sen University | Pd-1h as target in treatement of asthma |
| WO2018237287A1 (en) | 2017-06-22 | 2018-12-27 | Apexigen, Inc. | Anti-vista antibodies and methods of use |
| BR112020007755A2 (pt) | 2017-10-20 | 2020-10-20 | Pharmabcine Inc. | anticorpo anti-vista e uso do mesmo |
| AU2018360389B2 (en) | 2017-11-06 | 2024-09-19 | Aurigene Oncology Limited | Conjoint therapies for immunomodulation |
| EP3755350A4 (en) | 2018-02-23 | 2021-11-03 | TrueBinding, Inc. | TREATING CANCER BY BLOCKING THE INTERACTION OF VISTA AND HIS ASSOCIATION PARTNER |
| BR112020019083A2 (pt) * | 2018-03-21 | 2020-12-29 | Five Prime Therapeutics, Inc. | Anticorpos, ácido nucleico, composições, célula e métodos para preparar um anticorpo, para tratar câncer, para tratar uma doença infecciosa, para tratar uma inflamação, para a identificação de um anticorpo, para melhorar a eficácia antitumoral de um anticorpo, para melhorar a farmacocinética de um anticorpo, para selecionar um anticorpo, para melhorar a eficácia de anticorpos, para isolar anticorpos, para detectar vista em uma amostra e para tratar câncer |
| WO2019185163A1 (en) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Holdings Pte. Ltd. | Vista antigen-binding molecules |
| US20190300610A1 (en) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Pte. Ltd. | Vista antigen-binding molecules |
| PE20210687A1 (es) | 2018-07-11 | 2021-04-08 | Bristol Myers Squibb Co | Anticuerpos de union a vista a ph acido |
| CN109878421B (zh) | 2019-03-13 | 2020-11-03 | 浙江吉利控股集团有限公司 | 车辆坡道装置及汽车 |
| CN110563843A (zh) | 2019-07-25 | 2019-12-13 | 钟小泉 | 一种靶向人vista蛋白的单克隆抗体 |
-
2018
- 2018-03-13 PE PE2025000182A patent/PE20250933A1/es unknown
- 2018-03-13 CA CA3054067A patent/CA3054067A1/en active Pending
- 2018-03-13 SG SG11201907848YA patent/SG11201907848YA/en unknown
- 2018-03-13 JP JP2019549389A patent/JP7211961B2/ja active Active
- 2018-03-13 AU AU2018236218A patent/AU2018236218B2/en active Active
- 2018-03-13 EP EP18767615.0A patent/EP3595720A4/en active Pending
- 2018-03-13 KR KR1020247033048A patent/KR20240151866A/ko active Pending
- 2018-03-13 IL IL269240A patent/IL269240B1/en unknown
- 2018-03-13 BR BR112019019108-9A patent/BR112019019108A2/pt unknown
- 2018-03-13 IL IL326895A patent/IL326895A/en unknown
- 2018-03-13 WO PCT/US2018/022230 patent/WO2018169993A1/en not_active Ceased
- 2018-03-13 MY MYPI2019004903A patent/MY200609A/en unknown
- 2018-03-13 CN CN202410878453.8A patent/CN118894937A/zh active Pending
- 2018-03-13 US US16/493,712 patent/US11603406B2/en active Active
- 2018-03-13 CN CN201880031212.2A patent/CN110740749B/zh active Active
- 2018-03-13 KR KR1020197029923A patent/KR102715540B1/ko active Active
- 2018-03-13 PE PE2019001859A patent/PE20191708A1/es unknown
- 2018-03-14 TW TW112143312A patent/TWI890190B/zh active
- 2018-03-14 TW TW107108715A patent/TWI825010B/zh active
-
2019
- 2019-08-21 ZA ZA2019/05525A patent/ZA201905525B/en unknown
- 2019-09-12 CL CL2019002610A patent/CL2019002610A1/es unknown
- 2019-09-12 MX MX2024003316A patent/MX2024003316A/es unknown
- 2019-10-02 CO CONC2019/0010943A patent/CO2019010943A2/es unknown
-
2021
- 2021-10-21 CL CL2021002769A patent/CL2021002769A1/es unknown
-
2023
- 2023-01-12 JP JP2023002879A patent/JP7573659B2/ja active Active
- 2023-02-01 US US18/162,991 patent/US12195535B2/en active Active
-
2024
- 2024-10-15 JP JP2024179648A patent/JP2025023919A/ja active Pending
- 2024-11-25 US US18/958,201 patent/US20250206822A1/en active Pending
-
2025
- 2025-05-28 AU AU2025203967A patent/AU2025203967A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020509756A5 (https=) | ||
| JP2023061927A5 (https=) | ||
| CN102958537B (zh) | TNF-α结合蛋白 | |
| JP6647208B2 (ja) | 抗ｉｌ−１７抗体、その生産および使用のための方法 | |
| US11827701B2 (en) | IL-6 binding molecules | |
| AU2012347972B2 (en) | PDGF receptor beta binding polypeptides | |
| US11525005B2 (en) | Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof | |
| CN103459609A (zh) | TNF-α结合蛋白 | |
| JP2016517277A (ja) | ＴＮＦαに対して指向された二重特異的結合タンパク質 | |
| JP2022513420A5 (https=) | ||
| TW201041592A (en) | Anti-TNF-α antibodies and their uses | |
| TW201031421A (en) | IL-1 binding proteins | |
| TW201333033A (zh) | 雙可變域免疫球蛋白及其用途 | |
| TW201512219A (zh) | 針對ＩＬ－１β及／或ＩＬ－１７之雙特異性結合蛋白 | |
| RU2015115956A (ru) | Антитела, специфичные в отношении фактора роста тромбоцитов в, и их композиции и применения | |
| JP2020502233A5 (https=) | ||
| TW202104261A (zh) | 三特異性結合蛋白、方法及其用途 | |
| CN109689684B (zh) | 具有低免疫原性的抗体及其用途 | |
| TW202440636A (zh) | Ｃｄ１９／ｃｄ３８多特異性抗體 | |
| CA3164234A1 (en) | Multi-specific antibodies | |
| CN110114372A (zh) | 用于减少多特异性抗体聚集的抗体构架 | |
| US20230406942A1 (en) | Igf1r antibodies | |
| WO2019174637A1 (zh) | 一种针对tim-3的全人源化抗体分子、抗原结合片段及其医药用途 |